pharmaphorum Podcast

An increasing prevalence of immunodeficiency and autoimmune disorders has led to increasing demand for plasma-derived immunoglobulin therapies and a need for scalable and sustainable treatment solutions.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Jörg Schüttrumpf, MD, PhD, Chief Scientific Innovation Officer of Grifols and Chief Executive Officer at Biotest, a Grifols company. The conversation explores ...

A liquid biopsy is a blood test that detects signs of cancerous tumors, including tumour cells and cancer cell DNA.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid biopsies should become standard in oncology.

Newland explains how current US FDA-approved tests can detect some types of advanced cancers, predict prognosis, and help healthcare providers make ...

It goes without saying that drug pricing and accessibility in the United States are complex indeed.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Vinay Patel, an innovative pharmacist who's set out to transform the healthcare industry, about these intricacies.

Patel discusses some intriguing stories about crafting innovative solutions for employers, revitalising struggling independent pharmacies, and implemen...

Gefion is Denmark’s first AI supercomputer, named after a goddess in Danish mythology. It is operated by the Danish Centre for AI Innovation (DCAI), a company established with funding from the Novo Nordisk Foundation, the world’s wealthiest charitable foundation, as well as the Export and Investment Fund of Denmark.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tarek Samad, Lundbeck’s senior vice president an...

Illumina innovative sequencing and array technologies are fuelling groundbreaking advancements in life sciences research, translational and consumer genomics, and molecular diagnostics.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Markus Vossman, Germany general manager at Illumina, about innovative genomic applications and projects in the region.

Vossman discusses the genomics landscape, as well as next-gen...

The FDA recently announced that it will begin offering faster drug reviews to certain medicines, reducing the drug review process from approximately ten months to one or two months. This news follows a series of rapid changes from the FDA since the Trump administration took office.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Amy Bucher, chief behavioural officer at Lirio, a healthcare personalization pla...

In a new pharmaphorum podcast, guest Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials.

The conversation touches upon how large language models (or LLMs) can be gotten into production in regulated spaces – and why generic models won’t cut it in this domain – as well as the role of real-world data in quantifying and reducing patient burden.

You can listen to episode 233 of the p...

The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together dynamic female leaders to discuss the transformative role of artificial intelligence in life sciences. It is also a call to action: to ensure women are not only present, but pivotal in shaping the future of AI in healthcare.

In a new pharmaphorum podcast focused on the important and timely subject of women in AI,...

AI’s growing influence in pharma is transforming traditional drug discovery timelines.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Alan Roth, CEO of Oxford Drug Design, about the use of AI to accelerate discovery of new treatments for cancer, infectious diseases, and cystic fibrosis.

Roth discusses combining deep enzyme biology expertise with GenAI and targeting leucyl-tRNA synthetase.

You can listen to ...

AI and computational small molecule drug discovery approaches are helping to realise the potential of targeted protein degradation (TPD) in molecular glue development.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a company that’s specialises in next-gen TPD and which is progressing a pipeline of degrader therapeutics within oncology and inflammation.

Cro...

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Craig Eagle, Chief Medical Officer of Guardant Health, a precision medicine company that offers blood tests to inform cancer treatment decisions.

Eagle discusses Guardant’s participation in the National Cancer...

There is a world of difference between the NHS from its beginnings in 1948 and the NHS as it is now.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, for a conversation on her book, “Our NHS for better or worse?”.

Chambers discusses her personal experience as a GP in the NHS, including the discrimination...

CB1 inhibition is an approach that taps into the body’s natural metabolism to burn fat while preserving muscle for more sustainable weight loss. Unlike GLP-1s, which suppress appetite, CB1 inhibition activates fat-burning processes.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Punit Dhillon, CEO of Skye Bioscience, for a conversation on CB1 inhibitor antibodies in the obesity space.

Dhillon discusses GLP-1 w...

Technology and AI can help healthcare systems tackle the affordability challenge while ensuring patients still benefit from cutting-edge treatments.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Alfred Olivares, global managing partner, healthcare & medtech, at HTEC, in a conversation addressing how innovation can reach patients in a financially sustainable way.

Olivares discusses digital transformation t...

There are many efforts at the moment to transform the expensive, labour intensive, and high failure rate processes of drug discovery into automated drug design.

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail, as well as the importance of de...

A CDMO plays a crucial role in the pharmaceutical and biotechnology industries by providing comprehensive drug development and manufacturing services, enabling companies to efficiently bring new medicines to market.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sigma Mostafa, CSO at KBI BioPharma, about the role of CDMOs and the important factors companies should consider when selecting one.

Mostafa sets out ...

Drug shortages are a critical issue in the US, leaving patients and healthcare providers struggling. Compounding pharmacies, however, can curb drug shortages and help lessen this growing threat to the public's health. 

In a  new pharmaphorum podcast, web editor Nicole Raleigh speaks with Shawn Hodges, CEO of Revelation Pharma, a nationwide network of 503A and 503B compounding pharmacies, spanning across various locations.

Hodges di...

Intra-tumourally injected therapeutics represent a novel approach to cancer cell death, with high tumour dispersion and cell penetration properties.

To discuss the potential of these therapeutics to kill tumours and elicit an adaptive immune response within mere days of injection, pharmaphorum spoke with Lew Bender, CEO of Intensity Therapeutics Inc.

Bender discusses the possibility of shifting the oncological treatment paradigm wi...

There is a growing body of evidence on the role of inflammation in predicting heart health.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Sandeep Kulkarni, CEO of Tourmaline Bio, about addressing inflammation, and also the impact of AI and GLP-1s on cardiology clinical trials and drug development.

Kulkarni also discusses Tourmaline’s IL-6 inhibitor for atherosclerotic cardiovascular disease, and his hopes for ...